del Giglio, A <br/><br/>
XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.  [electronic resource] 

 -  BMC cancer  Nov 2008 
 - 332 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-8-332  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Analysis of Variance<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Breast Neoplasms, Male--drug therapy<br/>Docetaxel<br/>Double-Blind Method<br/>Doxorubicin--adverse effects<br/>Female<br/>Filgrastim<br/>Granulocyte Colony-Stimulating Factor--adverse effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Neutropenia--chemically induced<br/>Neutrophils--drug effects<br/>Recombinant Proteins<br/>Taxoids--adverse effects<br/>Treatment Outcome